The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Managing the progression of MDS to AML
Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, talks on the management of progression from myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML), highlighting the impact of having received previous hypomethylating agents (HMAs). Dr Brunner discusses the poor response of patients who progress to AML from MDS and have received HMA therapy prior to induction therapy, and gives an overview of alternative approaches. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Andrew M. Brunner, MD, has participated in consultancy work for Novartis, Acceleron, Agios, BMS/Celgene and Takeda.
